Xalacom

DRUG11 trials

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer, Alcon Research, Laboratoires Thea

Conditions

GlaucomaGlaucoma, Open AngleGlaucoma, Open-AngleGlaucoma, Open-angleOcular HypertensionOpen Angle Glaucoma

Phase 3

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

CompletedNCT00150267

PfizerGlaucoma, Open-Angle, Ocular Hypertension

Start: 2002-02-28Updated: 2008-11-05

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

CompletedNCT00159653

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Open-Angle, Ocular Hypertension

Start: 2005-07-31End: 2007-06-30Updated: 2021-02-21

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

CompletedNCT00219596

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Open Angle, Ocular Hypertension

Start: 2005-06-30End: 2006-09-30Target: 240Updated: 2021-02-18

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

CompletedNCT00277498

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Ocular Hypertension, Open Angle Glaucoma

Start: 2005-12-31End: 2007-06-30Target: 528Updated: 2021-02-18

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

CompletedNCT00383019

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Ocular Hypertension

Start: 2006-11-14End: 2007-10-01Updated: 2021-09-08

DuoTrav APS Versus XALACOM® in Ocular Surface Health

TerminatedNCT00912054

Alcon ResearchOcular Hypertension, Open Angle Glaucoma

Start: 2010-03-31End: 2011-05-31Updated: 2012-07-19

Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

CompletedNCT02278614

Laboratoires TheaOcular Hypertension, Open Angle Glaucoma

Start: 2014-12-31End: 2015-11-30Updated: 2017-04-28

Phase 4

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

CompletedNCT00140049

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Open Angle, Ocular Hypertension

Start: 2005-07-31End: 2006-07-31Target: 238Updated: 2021-02-18

Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.

CompletedNCT00143208

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Ocular Hypertension

Start: 2003-05-31End: 2006-04-30Target: 250Updated: 2021-02-21

Unknown Phase

Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

CompletedNCT00801437

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Open-angle

Start: 2008-10-31End: 2009-06-30Updated: 2021-02-18

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

CompletedNCT01206361

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Glaucoma, Ocular Hypertension

Start: 2010-02-28End: 2010-08-31Updated: 2021-02-02

Related Papers

Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.

2010-02-0136 citations